The validations confirm the completion of the applications and commence the scientific review process
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The proposed hospital will have a bed capacity of 300 beds and the investment in the project is expected to be around Rs. 500 crore
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
Subscribe To Our Newsletter & Stay Updated
